Media
-
Nov 9, 2020The Scottish Medicines Consortium (SMC) enables access to volanesorsen, a treatment for adults with familial chylomicronaemia syndrome (FCS)
LONDON, UK, 9 November 2020 – Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Scottish Medicines Consortium (SMC) has...
-
Nov 6, 2020Ionis and Akcea recognize FCS Awareness Day with global community efforts to celebrate unsung heroes
BOSTON and CARLSBAD, Calif., November 6, 2020 – Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize the 3rd annual Familial Chylomicronemia...
-
Nov 3, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen...
-
Oct 30, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award for the Best Biotechnology Product in 2020 in recognition of...
-
Oct 12, 2020Transaction creates a stronger, more efficient company
CARLSBAD, Calif., October 12, 2020 / PRNewswire/ – Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea...
-
Sep 18, 2020National Institute for Health and Care Excellence (NICE) issues a positive recommendation for volanesorsen to treat adults with Familial Chylomicronaemia Syndrome (FCS)
LONDON, UK, September 18, 2020 – Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc. (NASDAQ: AKCA), announced today that the National Institute for Health and Care Excellence...
-
Aug 31, 2020Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash
CARLSBAD, Calif., and BOSTON, August 31, 2020 – Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a...
-
Aug 29, 2020Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant, dose-dependent reductions in triglyceride levels, ANGPTL3 and additional lipid parameters compared to placebo
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data from the Phase 2 clinical trial...
-
Aug 29, 2020Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent reductions in triglyceride levels, apoC-III, and significant reductions in atherogenic lipoproteins
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data today from the Phase 2 study of...
-
Aug 24, 2020Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2...